Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of August 2021, with a specific transaction date of August 9, 2021. The report serves as a transaction notification regarding insider trading activity rather than a periodic financial performance report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a specific securities transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Acquisition of notional ADSs within an Executive Supplemental Savings Plan account.
- Price: $40.58 per ADS.
- Volume: 1,141.045 ADSs.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a change in the holdings of a Person Discharging Managerial Responsibilities (PDMR).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of a single transaction.
Important Facts for Investors
- Insider Identity: The transaction was executed by Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: The purchase was made within a GSK Executive Supplemental Savings Plan account, indicating a structured compensation or savings mechanism rather than an open-market discretionary trade.
- Market Price: The transaction occurred at $40.58 per ADS on August 9, 2021.
- Scope: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.